Last reviewed · How we verify
Akrinol (ACRISORCIN)
Acrisorcin (Akrinol) is a marketed antifungal agent specifically indicated for the treatment of Pityriasis versicolor. Its key strength lies in its mechanism of action, which effectively inhibits the growth of the fungus Malassezia, providing a targeted therapeutic approach. The primary risk to Acrisorcin is the expiration of its key composition patent in 2028, which could lead to increased competition from generic alternatives.
At a glance
| Generic name | ACRISORCIN |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
| First approval | 1982 |
Approved indications
- Pityriasis versicolor
Common side effects
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Akrinol CI brief — competitive landscape report
- Akrinol updates RSS · CI watch RSS